As an incubator for scientific innovations addressing unmet diagnostic and therapeutic needs, we encourage you to contact us to discuss how we might work together.
A Call to all Collaborators
Ethos Discovery is Agnostic to the source of good ideas
Our focus on outcomes rather than on ownership has created an open, transparent, and inclusive approach to science where all good ideas are advanced. Across our programmatic priorities we have over 50 ongoing collaborations around the world, including clinicians, drug and diagnostic developers, and a wide array of scientists from both human and animal health disciplines in the commercial, academic and non-profit sectors.
The Ethos Discovery team has specific and rigorous plans to address our scientific priorities. We focus our approach on achieving the desired outcomes associated with improving health for veterinary and human patients with complex medical problems. As a not-for-profit scientific organization, Ethos Discovery offers results from our studies free of charge, and without restriction, to parties interested in commercialization for human health. In doing so, we aim to contribute to the development of novel diagnostic and treatment options that lead to a cure for complex medical conditions such as cancer.
The similarity of disorders in pets and humans is widely recognized and it is likely the innovations we are working on will be useful for human patients in the future.
We are agnostic to the source of good ideas and invite all innovators to join us in our work. Please reach out to discuss your great ideas!
Ongoing collaborations and areas where we seek your involvement:
- Clinicians: Veterinary practitioners within and beyond Ethos are invited to participate in clinical trials and offer our innovations to their patients. Our perspective on “unmet needs” comes from Ethos clinicians who share their struggles and pain points in delivering optimal care. Our highly innovative science portfolio exists thanks to like-minded veterinarians, veterinary technicians, specialists and other members of the veterinary industry.
- Drug Developers: We welcome involvement and team work with groups seeking to answer research questions about the development of novel therapeutics. These novel approaches are show cased in our open clinical trials.
- Device Developers: Allured by our robust clinical annotation of samples and rapidly recruited prospective clinical cohorts, several groups seeking device validation have joined as collaborators. We welcome device developers to contact us, and look forward to working together.
- Diagnostic Developers: There is a unique opportunity to define the value proposition and validate novel biomarkers and other diagnostic assays through our clinical studies and trials. Most Ethos Discovery clinical trials include biospecimen collection plans to allow for the discovery and validation of biomarkers.
- Cross-species Scientists: Ethos Discovery aims to improve outcomes for both human and animal patients with complex medical conditions. Ideal collaborators in this area include scientists seeking to translate new knowledge from pet animals to humans and vice versa.
- Pet owners: Ethos Discovery only conducts clinical studies in pets with naturally occurring disease. We are grateful to owners of pets who are patients in our clinical trials, and for the trust they place in us and our approach. Pets diagnosed with a complex medical problem within the Ethos Discovery Scientific priorities are referred for enrollment in appropriate clinical studies and trials. In these cases, care for the patient will continue to be provided by the veterinarian or specialist at their own Ethos hospital. Since all participants are also patients, there are no placebo groups in our studies.
Scientific Programs in our Pipeline:
Follow the links below to learn more about each of our main programs. More information on our studies can be found by clicking the link in the sidebar.
- Hemangiosarcoma Program: Hemangiosarcoma (HSA) is an aggressive cancer in dogs that carries a poor prognosis with limited therapeutic options. Since HSA cases commonly involve emergency, surgery, internal medicine, and chemotherapy services, numerous specialty services throughout a hospital are impacted. This means that the unmet needs are recognized by all parts of the profession.
- Inflammatory CNS Disease Program: Necrotizing meningoencephalitis (NME) is a severe, progressive neurologic disease, overt clinical signs are often only noted after significant brain damage has already occurred. There is an unmet need for both an early diagnosis and more effective therapy.
- Innovations in Surgery: We are actively working on projects to develop and refine techniques and treatments aimed at minimizing surgery-related pain, complications, and morbidity, and maximizing patient recovery and return to function.
- Intestinal Dysbiosis Program: The micro-organisms of the intestinal tract constitute the intestinal microbiome. Alterations in the intestinal microbiome, referred to as “intestinal dysbiosis,” may play a role in diseases within the intestine, but also diseases distinct from the intestine, such as epilepsy, diabetes, wound healing, immune immune-mediated conditions, and cancer. An understanding of the effect of intestinal dysbiosis on the progression of various diseases, especially non-intestinal diseases, is currently lacking in both human and veterinary medicine. We hope to gain a better understanding of the possible influence of intestinal dysbiosis on a variety of non-intesinal diseases in veterinary patients.
- Novel Therapeutics Program: Drugs that would best fit this program include those that have an available active pharmaceutical ingredient (API) in the U.S., are not included in current veterinary-approved products, and would be well-suited for a science-based marketing approach instead of a direct-to-consumer approach.
- Sepsis Program: Sepsis is the result of severe infection, and has an unfortunately high mortality rate. Previous studies have shown that a timely sepsis diagnosis and rapid implementation of therapy is paramount to treatment success. A diagnostic test that could provide reliable prognostic information in septic patients could save lives.
Contact us to discuss your ideas! We look forward to hearing about how your team is approaching some of these complex medical conditions, your work and your ideas! Who knows, maybe this will be the start of a beautiful friendship! We take an agnostic approach to the source of good ideas, and want to work with like-minded individuals across all walks of life and both ends of the leash.